https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53995 Wed 28 Feb 2024 15:22:59 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55825 Wed 26 Jun 2024 16:18:30 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24535 Wed 23 Feb 2022 16:04:00 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48899 Wed 19 Apr 2023 16:39:48 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42046 Wed 17 Aug 2022 13:44:19 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:12275 Wed 11 Apr 2018 17:09:27 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5073 Wed 11 Apr 2018 15:43:57 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5074 Wed 11 Apr 2018 15:16:35 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:12179 Wed 11 Apr 2018 14:01:48 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5071 Wed 11 Apr 2018 13:20:04 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:9433 Wed 11 Apr 2018 13:04:58 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14434 Wed 11 Apr 2018 12:18:21 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24221 Wed 11 Apr 2018 11:05:38 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5069 Wed 11 Apr 2018 10:11:19 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55096 Wed 10 Apr 2024 08:45:54 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50838 Wed 09 Aug 2023 09:03:46 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26006 Wed 06 Apr 2022 14:02:24 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34422 Wed 04 Sep 2019 10:27:38 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29397 Wed 04 Sep 2019 10:24:26 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34421 Wed 04 Sep 2019 09:55:56 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49013 Wed 03 May 2023 12:24:08 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49597 Tue 23 May 2023 13:34:14 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:9233 Tue 20 Aug 2024 08:47:32 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37177 Tue 10 Sep 2024 13:15:36 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33616 Tue 10 Sep 2024 12:54:28 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31041 Tue 10 Sep 2024 12:47:37 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30164 Tue 10 Sep 2024 12:47:31 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22523 Tue 10 Sep 2024 12:41:02 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24533 Tue 10 Sep 2024 12:40:58 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22217 Cochrane Central Register of Controlled Trials) (all years), EMBASE (1974 -), MEDLINE (1950 -) and PsycINFO (1967 -). We also checked reference lists of relevant studies and reviews. We applied no date or language restrictions. Selection criteria: All randomised controlled trials of psychological therapies compared to a control, pharmacological therapy or other treatments in children or adolescents exposed to a traumatic event or diagnosed with PTSD. Data collection and analysis: Two members of the review group independently extracted data. If differences were identified, they were resolved by consensus, or referral to the review team. We calculated the odds ratio (OR) for binary outcomes, the standardised mean difference (SMD) for continuous outcomes, and 95% confidence intervals (CI) for both, using a fixed-effect model. If heterogeneity was found we used a random-effects model. Main results: Fourteen studies including 758 participants were included in this review. The types of trauma participants had been exposed to included sexual abuse, civil violence, natural disaster, domestic violence and motor vehicle accidents. Most participants were clients of a trauma-related support service. The psychological therapies used in these studies were cognitive behavioural therapy (CBT), exposure-based, psychodynamic, narrative, supportive counselling, and eye movement desensitisation and reprocessing (EMDR). Most compared a psychological therapy to a control group. No study compared psychological therapies to pharmacological therapies alone or as an adjunct to a psychological therapy. Across all psychological therapies, improvement was significantly better (three studies, n = 80, OR 4.21, 95% CI 1.12 to 15.85) and symptoms of PTSD (seven studies, n = 271, SMD -0.90, 95% CI -1.24 to -0.42), anxiety (three studies, n = 91, SMD -0.57, 95% CI -1.00 to -0.13) and depression (five studies, n = 156, SMD -0.74, 95% CI -1.11 to -0.36) were significantly lower within a month of completing psychological therapy compared to a control group. The psychological therapy for which there was the best evidence of effectiveness was CBT. Improvement was significantly better for up to a year following treatment (up to one month: two studies, n = 49, OR 8.64, 95% CI 2.01 to 37.14; up to one year: one study, n = 25, OR 8.00, 95% CI 1.21 to 52.69). PTSD symptom scores were also significantly lower for up to one year (up to one month: three studies, n = 98, SMD -1.34, 95% CI -1.79 to -0.89; up to one year: one study, n = 36, SMD -0.73, 95% CI -1.44 to -0.01), and depression scores were lower for up to a month (three studies, n = 98, SMD -0.80, 95% CI -1.47 to -0.13) in the CBT group compared to a control. No adverse effects were identified. No study was rated as a high risk for selection or detection bias but a minority were rated as a high risk for attrition, reporting and other bias. Most included studies were rated as an unclear risk for selection, detection and attrition bias. Authors' conclusions: There is evidence for the effectiveness of psychological therapies, particularly CBT, for treating PTSD in children and adolescents for up to a month following treatment. At this stage, there is no clear evidence for the effectiveness of one psychological therapy compared to others. There is also not enough evidence to conclude that children and adolescents with particular types of trauma are more or less likely to respond to psychological therapies than others. The findings of this review are limited by the potential for methodological biases, and the small number and generally small size of identified studies. In addition, there was evidence of substantial heterogeneity in some analyses which could not be explained by subgroup or sensitivity analyses. More evidence is required for the effectiveness of all psychological therapies more than one month after treatment. Much more evidence is needed to demonstrate the relative effectiveness of different psychological therapies or the effectiveness of psychological therapies compared to other treatments. More details are required in future trials in regards to the types of trauma that preceded the diagnosis of PTSD and whether the traumas are single event or ongoing. Future studies should also aim to identify the most valid and reliable measures of PTSD symptoms and ensure that all scores, total and sub-scores, are consistently reported.]]> Tue 10 Sep 2024 12:26:26 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52399 Tue 10 Oct 2023 18:07:39 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36394 Tue 07 Apr 2020 15:53:48 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36392 Tue 07 Apr 2020 15:18:29 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36389 Tue 07 Apr 2020 14:29:30 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32487 Thu 30 Apr 2020 13:39:02 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36425 Thu 30 Apr 2020 13:32:09 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36423 Thu 30 Apr 2020 11:19:04 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51242 Thu 25 Jan 2024 15:26:55 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53994 Thu 25 Jan 2024 13:10:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27028 Thu 17 Mar 2022 14:41:44 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54270 Thu 15 Feb 2024 14:31:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54265 Thu 15 Feb 2024 14:31:33 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30831 Thu 14 Apr 2022 11:05:25 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48855 Thu 13 Apr 2023 13:36:30 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31220 Sat 24 Mar 2018 08:43:22 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:9395 Sat 24 Mar 2018 08:39:36 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:8459 Sat 24 Mar 2018 08:38:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:8460 Sat 24 Mar 2018 08:38:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:8458 Sat 24 Mar 2018 08:38:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7912 Sat 24 Mar 2018 08:37:40 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:9622 Sat 24 Mar 2018 08:35:27 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7327 Sat 24 Mar 2018 08:35:13 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7886 Sat 24 Mar 2018 08:35:09 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:12515 Sat 24 Mar 2018 08:16:02 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:10520 Sat 24 Mar 2018 08:13:59 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:10037 Sat 24 Mar 2018 08:12:00 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:12306 2 = 79%). When the four trials by Boldt are excluded, the RR is 0.76 (95% CI 0.62 to 0.93). On average, PRP did not significantly reduce the total volume of RBC transfused (weighted mean difference [WMD] -0.69, 95%CI -1.93 to 0.56 units). Trials provided inadequate data regarding the impact of PRP on morbidity, mortality, and hospital length of stay. Trials were generally small and of poor methodological quality. Authors' conclusions: Although the results suggest that PRP is effective in reducing allogeneic RBC transfusion in adult patients undergoing elective surgery, there was considerable heterogeneity of treatment effects and the trials were of poor methodological quality. The available studies provided inadequate data for firm conclusions to be drawn regarding the impact of PRP on clinically important endpoints.]]> Sat 24 Mar 2018 08:11:35 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:10897 Sat 24 Mar 2018 08:09:04 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:10904 Sat 24 Mar 2018 08:07:43 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18267 Sat 24 Mar 2018 08:04:23 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5102 Sat 24 Mar 2018 07:48:49 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5104 Sat 24 Mar 2018 07:48:48 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28319 Ganoderma lucidum (also known as lingzhi or reishi) is a mushroom that has been consumed for its broad medicinal properties in Asia for over 2000 years. G lucidum is becoming increasingly popular in western countries as a complementary medicine for cardiovascular health. Objectives: To evaluate the effectiveness of G lucidum for the treatment of pharmacologically modifiable risk factors of cardiovascular disease in adults.Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL Issue 6 of 12, 2014) on The Cochrane Library, MEDLINE (OVID, 1946 to June week 3 2014), EMBASE (OVID, 1980 to 2014 week 26), Science Direct (1823 to 2013), Current Controlled Trials (1990 to 2013), Australian New Zealand Clinical Trials Registry (2005 to 2013), Chinese Biomedical Literature Database (2007 to 2013), Chinese Medical Current Contents (2007 to 2013) and other databases. We checked reference lists of included studies, contacted content experts and handsearched The International Journal of Medicinal Mushrooms. We applied no language or publication restrictions. Selection criteria: Randomised controlled trials and controlled clinical trials of G lucidum for the treatment of cardiovascular risk factors. Primary outcomes were blood glucose level, blood pressure and lipid profile. Data collection and analysis: Two authors independently selected trials, assessed risk of bias and cross checked data extraction and analysis. A third author arbitrated in the event of disagreement. Main results: Five trials with a total of 398 participants were eligible for inclusion. Of these, one study was published in Chinese and translated to English; one study was published but study authors provided the additional data used in this review; one study was unpublished and the study authors provided data; and two studies did not provide comparison group data suitable for statistical analyses. The three studies from which data were used for statistical analyses compared G lucidum (1.4 g to 3 g per day) to placebo over 12 to 16 weeks of intervention. Although inclusion criteria varied, all participants of these three studies had type 2 diabetes mellitus. Of the five included studies, risk of bias was low for one study and unclear for the remaining four. Results from two studies showed that G lucidum was not associated with statistically or clinically significant reduction in HbA1c (WMD -0.10%; 95% CI -1.05% to 0.85%; 130 participants), total cholesterol (WMD -0.07mmol/L; 95% CI -0.57 mmol/L to 0.42 mmol/L; 107 participants ), low-density lipoprotein cholesterol (WMD 0.02 mmol/L; 95% CI -0.41 mmol/L to 0.45 mmol/L; 107 participants), or body-mass index (WMD -0.32 kg/m²; 95% CI -2.67 kg/m² to 2.03 kg/m²; 107 participants). All other analyses were from a single study of 84 participants. We found no improvement for fasting plasma glucose (WMD 0.30 mmol/L; 95% CI -0.95 mmol/L to 1.55 mmol/L). Measures of post-prandial blood glucose level found inconsistent results, being in favour of placebo for '2-hour post-prandial blood glucose' (WMD 0.7 mmol/L; 95% CI 0.29 mmol/L to 1.11 mmol/L) and in favour of G lucidum for 'plasma glucose under the curve at 4th hour' (WMD -49.4mg/dL/h; 95% CI -77.21 mg/dL/h to -21.59 mg/dL/h). As the Minimal Clinical Important Differences are unknown, the clinical significance of this effect is unclear. There were no statistically significant differences between groups for blood pressure or triglycerides. Participants who took G lucidum for four months were 1.67 times (RR 1.67 95% CI 0.86 to 3.24) more likely to experience an adverse event than those who took placebo but these were not serious side effects. Authors' conclusions: Evidence from a small number of randomised controlled trials does not support the use of G lucidum for treatment of cardiovascular risk factors in people with type 2 diabetes mellitus. Future research into the efficacy of G lucidum should be placebo-controlled and adhere to clinical trial reporting standards.]]> Sat 24 Mar 2018 07:25:08 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:4776 Sat 24 Mar 2018 07:20:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:4775 Sat 24 Mar 2018 07:20:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52861 100, one contributing to meta‐analysis), mean age range 27 to 54 years). We identified one ongoing study and three studies awaiting classification. One study was synthesised narratively, and another involved participants specifically with asthma‐COPD overlap. Most programmes were outpatient‐based, lasting from three to four weeks (inpatient) or eight to 12 weeks (outpatient). Education or self‐management components included breathing retraining and relaxation, nutritional advice and psychological counselling. One programme was specifically tailored for people with severe asthma. Pulmonary rehabilitation compared to usual care may increase maximal oxygen uptake (VO2 max) after programme completion, but the evidence is very uncertain for data derived using mL/kg/min (MD between groups of 3.63 mL/kg/min, 95% confidence interval (CI) 1.48 to 5.77; 3 studies; n = 129) and uncertain for data derived from % predicted VO2 max (MD 14.88%, 95% CI 9.66 to 20.1%; 2 studies; n = 60). The evidence is very uncertain about the effects of pulmonary rehabilitation compared to usual care on incremental shuttle walk test distance (MD between groups 74.0 metres, 95% CI 26.4 to 121.4; 1 study; n = 30). Pulmonary rehabilitation may have little to no effect on VO2 max at longer‐term follow up (9 to 12 months), but the evidence is very uncertain (MD −0.69 mL/kg/min, 95% CI −4.79 to 3.42; I2 = 49%; 3 studies; n = 66). Pulmonary rehabilitation likely improves functional exercise capacity as measured by 6‐minute walk distance, with MD between groups after programme completion of 79.8 metres (95% CI 66.5 to 93.1; 5 studies; n = 529; moderate certainty evidence). This magnitude of mean change exceeds the minimally clinically important difference (MCID) threshold for people with chronic respiratory disease. The evidence is very uncertain about the longer‐term effects one year after pulmonary rehabilitation for this outcome (MD 52.29 metres, 95% CI 0.7 to 103.88; 2 studies; n = 42). Pulmonary rehabilitation may result in a small improvement in asthma control compared to usual care as measured by Asthma Control Questionnaire (ACQ), with an MD between groups of −0.46 (95% CI −0.76 to −0.17; 2 studies; n = 93; low certainty evidence); however, data derived from the Asthma Control Test were very uncertain (MD between groups 3.34, 95% CI −2.32 to 9.01; 2 studies; n = 442). The ACQ finding approximates the MCID of 0.5 points. Pulmonary rehabilitation results in little to no difference in asthma control as measured by ACQ at nine to 12 months follow‐up (MD 0.09, 95% CI −0.35 to 0.53; 2 studies; n = 48; low certainty evidence). Pulmonary rehabilitation likely results in a large improvement in quality of life as assessed by the St George's Respiratory Questionnaire (SGRQ) total score (MD −18.51, 95% CI −20.77 to −16.25; 2 studies; n = 440; moderate certainty evidence), with this magnitude of change exceeding the MCID. However, pulmonary rehabilitation may have little to no effect on Asthma Quality of Life Questionnaire (AQLQ) total scores, with the evidence being very uncertain (MD 0.87, 95% CI −0.13 to 1.86; 2 studies; n = 442). Longer‐term follow‐up data suggested improvements in quality of life may occur as measured by SGRQ (MD −13.4, 95% CI −15.93 to −10.88; 2 studies; n = 430) but not AQLQ (MD 0.58, 95% CI −0.23 to 1.38; 2 studies; n = 435); however, the evidence is very uncertain. One study reported no difference between groups in the proportion of participants who experienced an asthma exacerbation during the intervention period. Data from one study suggest adverse events attributable to the intervention are rare. Overall risk of bias was most commonly impacted by performance bias attributed to a lack of participant blinding to knowledge of the intervention. This is inherently challenging to overcome in rehabilitation studies. Authors' conclusions: Moderate certainty evidence shows that pulmonary rehabilitation is probably associated with clinically meaningful improvements in functional exercise capacity and quality of life upon programme completion in adults with asthma. The certainty of evidence relating to maximal exercise capacity was very low to low. Pulmonary rehabilitation appears to confer minimal effect on asthma control, although the certainty of evidence is very low to low. Unclear reporting of study methods and small sample sizes limits our certainty in the overall body of evidence, whilst heterogenous study designs and interventions likely contribute to inconsistent findings across clinical outcomes and studies. There remains considerable scope for future research.]]> Mon 30 Oct 2023 10:01:13 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46644 Mon 28 Nov 2022 17:01:24 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:12181 Mon 26 Aug 2024 10:14:51 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:11799 Mon 26 Aug 2024 10:05:04 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28884 Mon 19 Aug 2024 14:50:08 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51776 Mon 18 Sep 2023 15:03:50 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44592 Mon 17 Oct 2022 14:39:26 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23309 Mon 12 Aug 2024 19:20:22 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:35765 Mon 09 Sep 2024 19:52:26 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:35252 Mon 09 Sep 2024 14:55:33 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52344 50 years of age versus > 70 years of age) across different studies, as this has previously been shown to influence results.]]> Mon 09 Oct 2023 14:57:37 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46708 Mon 06 May 2024 15:17:10 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51412 Mon 04 Sep 2023 14:52:36 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34946 Mon 02 Dec 2019 15:21:09 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:35090 Fri 30 Aug 2019 17:12:47 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36427 Fri 28 May 2021 12:24:03 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47750 Fri 27 Jan 2023 09:56:56 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27087 Fri 24 May 2019 12:28:47 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51909 Fri 22 Sep 2023 10:25:28 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40689 Fri 22 Jul 2022 11:57:15 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52657 Fri 20 Oct 2023 09:10:15 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46946 Fri 09 Dec 2022 14:14:31 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36755 464 participants) or staffing models (1 study, 647 participants) reduces nursing-staff turnover, or if primary nursing (2 studies, >138 participants) reduces costs, as we assessed the evidence for these outcomes to be of very low certainty.]]> Fri 03 Jul 2020 11:18:42 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51372 Fri 01 Sep 2023 13:41:20 AEST ]]>